IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.410
-0.090 (-6.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
IceCure Medical Revenue
IceCure Medical had revenue of $662.00K in the quarter ending September 30, 2024, with 102.45% growth. This brings the company's revenue in the last twelve months to $3.67M, up 26.02% year-over-year. In the year 2023, IceCure Medical had annual revenue of $3.23M with 4.67% growth.
Revenue (ttm)
$3.67M
Revenue Growth
+26.02%
P/S Ratio
18.55
Revenue / Employee
$47,675
Employees
77
Market Cap
79.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | -1.87M | -32.61% |
| Dec 31, 2019 | 5.74M | 1.70M | 42.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ICCM News
- 18 days ago - IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision - PRNewsWire
- 26 days ago - IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China - PRNewsWire
- 5 weeks ago - IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America - PRNewsWire
- 6 weeks ago - IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule - PRNewsWire
- 7 weeks ago - European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology - PRNewsWire
- 2 months ago - Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - PRNewsWire
- 3 months ago - IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - PRNewsWire